AdminMed

Scientists at the Shiley Center for Orthopaedic Research and Education at Scripps Clinic, La Jolla, California, USA, published their research where they used AdminPatch microneedle arrays for holding embryonic stem cell (ESC) hydrogel constructs: Shawn P. Grogan, Nicholas E. Glembotski, and Darryl D. D'Lima, "ALK-5 Inhibitors for Efficient Derivation of Mesenchymal Stem Cells from Human Embryonic Stem Cells," Tissue Engineering Part A, Mar 2023, 127-140. Based on the publication, the qualitative benefits of using AdminPatch microneedle arrays for holding embryonic stem cell (ESC) hydrogel constructs include: ? Facilitation of Chondrogenic Tissue Formation: The AdminPatch microneedle arrays support the formation of chondrogenic tissue from ESC-derived mesenchymal stem cells (MSCs) encapsulated in extracellular matrix (ECM)-fibrin hydrogel, enabling effective differentiation and maturation into cartilage-like tissue. ? Maintenance of Construct Integrity: The microneedle arrays play a crucial role in maintaining the integrity and shape of the ECM-fibrin hydrogel constructs during the culture period. This structural support is essential for the development of mechanically stable constructs. ? Enhanced Cartilage Regeneration Capabilities: The combination of the AdminPatch microneedle arrays with ECM-fibrin hydrogel constructs loaded with ESC-derived MSCs demonstrates enhanced capabilities for cartilage regeneration, as evidenced by the formation of high-quality neocartilage tissues. ? Successful Integration with Host Tissue: The study shows that the constructs can integrate well with ex vivo osteoarthritic cartilage, suggesting that the microneedle arrays can facilitate the delivery and integration of regenerative constructs into diseased or damaged cartilage. ? Versatility in Stem Cell Therapy Applications: The use of AdminPatch microneedle arrays for holding ESC hydrogel constructs underscores the versatility and potential of microneedle-based platforms in enhancing the delivery and efficacy of stem cell therapies for cartilage regeneration and possibly other therapeutic applications. These qualitative benefits highlight the potential of AdminPatch microneedle arrays in advancing regenerative medicine, particularly in the field of cartilage repair and regeneration.

AdminPen hollow microneedle array injection devices (Ho-MNs) were successfully tested for injection of teriflunomide-loaded solid lipid nanoparticles for the treatment of rheumatoid arthritis. Heba Abd-El-Azim, Haidy Abbas, Nesrine S. El Sayed, Ahmed M. Fayez, Mariam Zewail, "Non-invasive management of rheumatoid arthritis using hollow microneedles as a tool for transdermal delivery of teriflunomide loaded solid lipid nanoparticles," International Journal of Pharmaceutics, Volume 644, 2023, 123334. Based on the publication regarding the AdminPen hollow microneedle array devices (Ho-MNs) used for the delivery of teriflunomide encapsulated in solid lipid nanoparticles (TER-SLNs), the following quantitative benefits were identified: ? Minimally Invasive and Efficient Drug Delivery: The AdminPen hollow microneedles are designed to enable transdermal or intradermal delivery of liquid formulations, comprising 43 sharp-edged microneedle shafts for efficient drug delivery without needle blockage. Their structure facilitates direct drug administration to the inflammation sites, significantly enhancing the treatment's effectiveness. ? Reduced Risk of Skin Infection: Upon application, the AdminPen device creates tiny micropores in the skin that collapse and the skin barrier is quickly restored after the microneedles are removed, eliminating the risk of skin infection. This feature underscores the safety of using Ho-MNs for drug delivery. ? Superiority in Reducing Inflammation and Healing RA: The combination of TER-SLNs with AdminPen hollow microneedles demonstrated significant efficacy in reducing inflammation and healing Rheumatoid Arthritis (RA) in rats, compared to other methods. This combination could represent a promising non-invasive and self-administering alternative for RA treatment. ? Painless and Self-Administering Treatment Modality: The AdminPen hollow microneedles, combined with the nanoencapsulation of TER-SLNs, offer a painless and self-administering treatment modality. This approach not only improves patient compliance but also has the potential to replace invasive intra-articular injections. ? Potential Next Generation Anti-Arthritic Drug Delivery System: The innovative combination of MNs and nanotechnology platforms, exemplified by the AdminPen hollow MNs and TER-SLNs, is considered the next generation of anti-arthritic drug delivery systems, showcasing a significant advancement in RA treatment methodologies. This study highlights the promising implications of combining hollow microneedle technology with nanotechnology for non-invasive, effective, and patient-friendly treatment options for RA.

The talented group of scientists from Mercer University and Centers for Disease Control and Prevention, Atlanta, GA, used our microneedle array devices to perform the delivery of Adjuvanted Microparticulate HPV16 Vaccines and summarized their results in the following publication: Vo, Trinh Phuong, Gitika Panicker, Kimberly Braz-Gomes, Ashwin C. Parenky, Ira Rajbhandari, Mangalathu S. Rajeevan, Elizabeth R. Unger, Martin J. D’Souza, and Mohammad N. Uddin. 2022. "Enhanced Immunogenicity of Adjuvanted Microparticulate HPV16 Vaccines Administered via the Transdermal Route" Pharmaceuticals 15, no. 9: 1128. Based on the results of the study, the quantitative benefits of using AdminPatch microneedle array devices are: ? Enhanced Immunogenicity: The AdminPatch microneedle array devices were used to deliver an HPV16 vaccine, which demonstrated enhanced immunogenicity in preclinical models. The microneedle delivery of the vaccine elicited robust immune responses, which were significantly higher than those observed with intramuscular injection. ? High Encapsulation Efficiency: For the microparticulate (MP) vaccine formulation, the encapsulation yield was notably high at 80.5 ± 0.85%, indicating efficient incorporation of the HPV16 antigen into the microparticles, essential for maintaining the vaccine's integrity and immunogenicity. ? Significant Immune Activation: The microparticulate vaccines, when administered intradermally using AdminPatch, showed a substantial expansion of crucial immune cell populations. Specifically, there was a significant increase in CD4+, CD45R, CD27, and CD62L cell populations in vaccinated mice, demonstrating the vaccine's effectiveness in activating both innate and adaptive immune responses. ? Robust Antibody Production: The study reported a marked elevation in HPV16-specific IgG antibodies in the group receiving the microparticulate vaccine compared to those administered antigen solutions, highlighting the enhanced immunogenicity offered by the microparticulate form and the AdminPatch delivery system. ? Effective Memory B-Cell Generation: In the lymph nodes, memory B-cell counts were significantly higher in the microparticulate vaccine groups, with 27.2% and 25.5% for different formulations, compared to only 7.7% in the positive control group, indicating a strong, sustained immunological memory response. ? Enhanced Seropositivity with Optimized Formulation: Adjustments in the vaccine formulation, including changes in polymer matrix concentrations and adjuvant types, led to increased seropositivity. Specifically, using a prime dose of 20 μg HPV16 VLPs/mouse, which is two times greater than the initial formulation, enhanced the immune response, indicating the system's adaptability for improved outcomes. These points underscore the AdminPatch microneedle array devices' effectiveness in delivering microparticulate vaccines, enhancing immunogenic responses, and offering a promising strategy for improved HPV vaccination protocols.

A great recent scientific review by Kumbhar, P.R., Kumar, P., Lasure, A.?et al.?"An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success," published in?Discover Nano?18, 156 (2023) (https://lnkd.in/gM4SnQ_3), references the following benefits of the AdminPen? liquid injection devices for the delivery of particulate cancer vaccines: 1. Enhanced Tumor Suppression: MN-based particulate vaccine delivery showed approximately five times more tumor suppression compared to non-vaccinated animals. 2. Improved Efficacy in Combination Therapy: When combined with IL-2 & IL-12, there was about nine times more tumor suppression than the control vaccine nanoparticle alone. 3. Increased Immune Response: The use of AdminPen? resulted in increased serum IgG1, IgG2a, and IgG titers, as well as activation of CD4+ T-cells, CD8+ T-cells, and NK cells, indicating a strong humoral and cellular immune response. 4. Effective Transdermal Delivery: The AdminPen? facilitated efficient transdermal delivery, which is more advantageous due to better on-site delivery leading to immune cell activation. 5. Reduction in Tumor Volume: In a study involving chemo-photodynamic therapy against breast cancer, tumor volume was reduced approximately 3.5-fold after 15 days of treatment using the AdminPen? device for delivery. These benefits highlight the effectiveness of the AdminPen? in enhancing the immune response and suppressing tumor growth, demonstrating its significant potential in cancer vaccine delivery.

Novel Drug Delivery Systems In Cancer Therapy Market Outlook and Geography Forecast till 2031 Novel Drug Delivery Systems In Cancer Therapy Market Size, Share & Trends Analysis Report By Product (Nanoparticles{Liposomes, Polymers, Micelles, Other nanoparticles, Embolization particles, PVA particles, Drug-eluting beads, Liquid emboli, Other embolization particles}), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031 IMIR Market Research Pvt. Ltd. ?? ?????? ???????? ???????????? ???? ???????????????????? ?????????? ?? https://lnkd.in/dw2AjzJ7 ???????? ???????? ?????? ?????????????? ??????:?? Abbott AbCellera Abo Pharmaceuticals AC Immune AdminMed Advaxis Pharmaceuticals AELIX Therapeutics Aeras Aesica Pharmaceuticals Ltd Affinivax Inc. AFFiRiS AG Agenus AgResearch Aimmune Therapeutics AIVITA Biomedical, Inc. AJ Vaccines AKTIV-DRY, LLC AlphaVax Altimmune, Inc. American Association for Cancer Research Antares Pharma Inc. Apogee Technology Araclon Biotech, S.L. Archivel Farma S.L. Astellas Pharma AstraZeneca Australian Respiratory and Sleep Medicine Institute AXON Neuroscience BARR LABS Battelle Bavarian Nordic BCN Peptides BD Beijing Minhai Biotechnology Co., Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. #drugdelivery #lnp #microagulhamento #pharmaceuticals #therapeutic #vaccine #pharmaceutical #rna #dna #drugmanufacturing #fda #university #lipid #therapeutics #nanoparticle #formulation #commercial #polymernanoparticle #cdmo #mrnavaccines #preclinical #vaccines #mrna #clinical #sterile #pharmaceuticalmanufacturing #sterileprocessing #toxicology #fillandfinish #dermatologia